Literature DB >> 22964341

Nebulized lidocaine in the treatment of intractable cough.

Kelly Truesdale1, Adham Jurdi.   

Abstract

Cough is one of the most common symptoms prompting patients to be seen by health care providers in the United States. Persistent cough can disrupt daily activities such as conversation, eating, breathing, and sleeping, and it can become extremely debilitating both physically and mentally. Pharmacological treatments include dextramethorphan, opioid cough suppressants, benzonatate, inhaled ipratropium, and guaifenesin. Successful cough suppression has also been demonstrated in several studies with the use of nebulized lidocaine. Nebulized lidocaine also appears to be well tolerated by patients with minimal side effects including dysphonia, oropharyngeal numbness, and bitter taste. Studies conducted thus far have been small, so larger randomized control trials comparing nebulized lidocaine to placebo need to be conducted in the future.

Entities:  

Keywords:  cough; intractable cough; lidocaine; nebulized; nebulized lidocaine; palliative

Mesh:

Substances:

Year:  2012        PMID: 22964341     DOI: 10.1177/1049909112458577

Source DB:  PubMed          Journal:  Am J Hosp Palliat Care        ISSN: 1049-9091            Impact factor:   2.500


  3 in total

1.  Protective effects of lidocaine on polycystic ovary syndrome through modulating ovarian granulosa cell physiology via PI3K/AKT/mTOR pathway.

Authors:  Haixia Xiong; Qiong Hu; Qun Jiang
Journal:  Cytotechnology       Date:  2022-02-24       Impact factor: 2.058

2.  Sufentanil EC50 for endotracheal intubation with aerosol inhalation of carbonated lidocaine by ultrasonic atomizer.

Authors:  Qiaoqiao Xu; Zhiqiang Zhou; Ling Ai; Jieqiong Liu; Xuebi Tian
Journal:  BMC Anesthesiol       Date:  2021-05-12       Impact factor: 2.217

Review 3.  The Prospect for Potent Sodium Voltage-Gated Channel Blockers to Relieve an Excessive Cough.

Authors:  M Brozmanova; N Pavelkova
Journal:  Physiol Res       Date:  2020-03-27       Impact factor: 1.881

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.